ClinicalTrials.gg
Active, not recruitingNCT07075640Updated Jul 30, 2026

A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants

A Phase 1 interventional study of AG-236 and Placebo in Healthy Participants, sponsored by Agios Pharmaceuticals, Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary purpose of this study is to assess the safety and tolerability of a single dose of AG-236 administered subcutaneously in healthy participants.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, of any race, between 18 and 55 years of age, inclusive.

    1. Females must be of nonchildbearing potential.
    2. Males must agree to use .
    3. Males must agree not to donate sperm during the study and for 90 days or 5-half-lives of AG-236 in plasma, whichever is longer, after dose administration.
  • between 18.0 and 32.0 kilograms per square meter (kg/m2), inclusive.
  • Body weight between 50 and 100 kg, inclusive.
  • In good health, as determined by no findings from medical history, 12-lead (ECG) and vital sign measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert's syndrome based on total and direct ] is not acceptable) at screening and check-in, and from the physical examination at screening, as assessed by the investigator or designee.
  • Able to comprehend and willing to sign the form (ICF) and abide by the study restrictions.

Exclusion criteria

Exclusion Criteria

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator or designee.
  • History of , with the exception of adequately treated non-melanomatous skin carcinoma.
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator or designee.
  • History or presence of iron deficiency or iron deficiency anemia and/or currently receiving oral or parenteral iron supplementation as treatment for those conditions or deemed high risk of iron deficiency as determined by the investigator.

    1. Males: ferritin \<30 nanogram per millilitres (ng/mL) and/or transferrin saturation (TSAT): ≤25%.
    2. Females: ferritin \<30 ng/mL and/or TSAT: ≤20%.
  • Fever (oral body temperature >38°C) or symptomatic viral or bacterial infection within 2 weeks prior to screening; evidence of intestinal infection (such as a participant-reported history of gastrointestinal symptoms [eg, nausea, vomiting, diarrhea] that are consistent, in the opinion of the investigator, with an acute viral or bacterial process) within 30 days prior to screening.
  • Confirmed systolic blood pressure >140 or \<90 millilitres of mercury (mmHg), diastolic blood pressure >90 or \<50 mmHg, or pulse rate >100 or \<40 beats per minute. If any parameter is out of range, measurements should be repeated twice. Participants will be excluded if the average of the 3 measurements are outside of the corresponding reference range.
  • abnormality, as determined by the investigator, on performed at screening or check-in or any of the following:

    1. corrected for heart rate using Fridericia's formula (QTcF) >450 milliseconds (ms) in males or >470 ms in females, confirmed by calculating the mean of the triplicate values obtained
    2. history of additional risk factors for torsades de pointes (eg, heart failure, hypokalemia, or family history of long QT syndrome).
    3. Clinical laboratory values that are outside the normal reference range and are considered clinically significant, as determined by the investigator.
    4. Clinical laboratory values for (Hb) for males \<13.8 grams per decilitres g/dL and females \<12.1 g/dL.
    5. Clinical laboratory values for (AST), alanine aminotransferase (ALT) and/or total >1 × (ULN).
  • Participants will be excluded if a single repeat confirms the result.
  • Positive hepatitis panel and/or positive test.
  • Participants whose results are compatible with prior immunization may be included.
  • Clinical laboratory value for (PTT) >1 × ULN and/or International Normalized Ratio (INR) >1.2. Participants will be excluded if a single repeat confirms the result.
  • Administration of any vaccine within 30 days prior to dosing.
  • Use or intend to use during the study duration any prescription medications/products, including hormone replacement therapy, within 28 days prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.
  • Use or intend to use during the study duration any slow-release medications/products considered to still be active within 28 days prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.
  • Use or intend to use during the study duration any nonprescription medications/products including vitamins (including iron-containing multivitamins), minerals, biotin supplements, recreational drugs, or phytotherapeutic/herbal/plant-derived preparations within 28 days prior to dosing, considered to potentially impact participant safety or the objectives of the study, as determined by the investigator or designee.
  • Participation in a clinical study involving administration of an IMP (new chemical entity) in the past 30 days or 5 half-lives of that drug (if known) prior to dosing, whichever is longer.
  • Have previously completed or withdrawn from this study or any other study investigating AG-236 and have previously received AG-236.
  • Alcohol consumption of >14 units per week for males and females. One unit of alcohol equals 12 ounces (oz) (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine.
  • Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.
  • History of alcoholism or drug/chemical abuse within 2 years prior to check-in.
  • Use of tobacco- or nicotine-containing products within 3 months prior to check-in, or positive cotinine at screening or check-in.
  • Have special dietary restrictions or inability to consume standard meals as required in the study.
  • Receipt of blood products within 2 months prior to check in.
  • Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to screening, or from 6 weeks prior to screening.
  • Poor peripheral venous access.
  • Participants who, in the opinion of the investigator or designee, should not participate in this study.
  • Increased risk of thrombosis, as determined by the investigator or designee.
  • Clinical laboratory value for homocysteine >1 × ULN.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment Group A

    Participants will receive a single dose of AG-236 at dose level 1 or placebo on Day 1 under fasted conditions.

    Drug: AG-236 · Drug: Placebo

  • Experimental
    Treatment Group B

    Participants will receive a single dose of AG-236 at dose level 2 or placebo on Day 1 under fasted conditions.

    Drug: AG-236 · Drug: Placebo

  • Experimental
    Treatment Group C

    Participants will receive a single dose of AG-236 at dose level 3 or placebo on Day 1 under fasted conditions.

    Drug: AG-236 · Drug: Placebo

Interventions

  • DrugAG-236

    Subcutaneous (SC) Injection

  • DrugPlacebo

    SC Injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) by Type, Severity, and Relationship to Study Drug

    Time frame: Up to Day 57

Secondary outcomes

  1. Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of AG-236

    Time frame: Predose and multiple time points postdose from Day 1 to Day 57

  2. Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of AG-236

    Time frame: Predose and multiple time points postdose from Day 1 to Day 57

  3. Maximum Observed Plasma Concentration (Cmax) of AG-236

    Time frame: Predose and multiple time points postdose from Day 1 to Day 57

  4. Percentage of Area Under the Concentration-Time Curve due to Extrapolation From the Last Quantifiable Concentration to Infinity (AUC%extrap) of AG-236

    Time frame: Predose and multiple time points postdose from Day 1 to Day 57

  5. Time to Last Measurable Concentration (tlast) of AG-236

    Time frame: Predose and multiple time points postdose from Day 1 to Day 57

  6. Time to Reach Maximum Observed Plasma Concentration (tmax) of AG-236

    Time frame: Predose and multiple time points postdose from Day 1 to Day 57

  7. Terminal Elimination Half-Life (t1/2) of AG-236

    Time frame: Predose and multiple time points postdose from Day 1 to Day 57

  8. Apparent Total Body Clearance (CL/F) of AG-236

    Time frame: Predose and multiple time points postdose from Day 1 to Day 57

  9. Apparent Volume of Distribution (Vz/F) of AG-236

    Time frame: Predose and multiple time points postdose from Day 1 to Day 57

  10. Amount of Unchanged AG-236 Excreted in Urine From Day 1 to Day 3 (Aet1-t2)

    Time frame: Predose and multiple time points postdose from Day 1 to Day 3

  11. Cumulative Amount of Unchanged AG-236 Excreted in Urine (Cum Aeu)

    Time frame: Predose and multiple time points postdose from Day 1 to Day 3

  12. Percentage of AG-236 Dose Excreted Unchanged in Urine From Day 1 to Day 3 (fet1-t2)

    Time frame: Predose and multiple time points postdose from Day 1 to Day 3

  13. Cumulative Percentage of AG-236 Dose Excreted Unchanged in Urine (Cum fe)

    Time frame: Predose and multiple time points postdose from Day 1 to Day 3

  14. Renal Clearance (CLR) of AG-236

    Time frame: Predose and multiple time points postdose from Day 1 to Day 3

  15. Change From Baseline in Serum Hepcidin Levels

    Time frame: Baseline, Days 2, 3, 8, 29, and 57

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Feb 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Jul 20, 2025
StartActual
Jul 7, 2025
Primary completionActual
Feb 11, 2026
CompletionEst.
Aug 31, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07075640
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Jul 7, 2025
Primary completion
Feb 11, 2026
Completion
Aug 31, 2026 (estimated)
Last update
Jul 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion